Satellos Bioscience Inc. has announced encouraging data from the company’s Phase 1b open-label study of SAT-3247, an oral small molecule inhibitor of AAK, designed to address progressive muscle loss by restoring muscle regeneration in response to damage. The 28-day, early-stage trial included five adult Duchenne patients (ages 20–27), and demonstrated early signs that SAT-3247 may have the potential to positively affect grip strength.
Results indicate that the Phase 1b open-label trial of SAT-3247 met the primary endpoint of safety and tolerability. Additionally, grip strength was measured using the standardized MyoGrip measurement tool, with a trend of improved grip strength reported at 28 days.
Satellos has indicated that it plans to begin an 11-month follow-up study, which has already received approval in Australia to enroll up to 10 adults with Duchenne. First-patient dosing is expected in July 2025, pending qualification of the clinical site. The study will incorporate additional non-invasive measurements, including MRI imaging to assess possible changes in muscle and will measure grip strength every three months to evaluate whether the observed improvements continue.
According to Satellos, improvements in muscle strength have consistently been an early signal of a possible drug effect in the company’s preclinical studies in multiple animal models. Satellos believes the findings from this Phase 1b study support its plan to advance SAT-3247 into a placebo-controlled Phase 2 proof-of-concept trial in pediatric patients, expected to begin in the third quarter of 2025.
Read Satello’s press release here.
The post Satellos Announces Positive Functional Data from Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne appeared first on Parent Project Muscular Dystrophy.